Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective study
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | São Paulo medical journal (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802022000300372 |
Resumo: | ABSTRACT BACKGROUND: Favipiravir is generally used in treating coronavirus disease 2019 (COVID-19) pneumonia in Turkey. OBJECTIVE: To determine the side effects of favipiravir and whether it is a good treatment option. DESIGN AND SETTING: Retrospective study conducted in Atatürk Chest Diseases and Chest Surgery Training and Research Hospital, Ankara, Turkey. METHODS: 357 patients who completed favipiravir treatment at the recommended dose were included. 37 patients with drug side effects and 320 patients without drug side effects were examined in two groups. RESULTS: Side effects were observed in 37 (10.36%) out of 357 patients using favipiravir. The most common side effect was liver dysfunction, in 26 (7.28%) of the patients. The following other side effects were also observed: diarrhea (1.4%), nausea (0.84%), abdominal pain (0.28%) and thrombocytopenia (0.28%). One patient (0.28%) presented both increased transaminases and nausea. CONCLUSION: In this study, it was determined that favipiravir may constitute an alternative for treating COVID-19 pneumonia given that its side effects are generally well tolerated and not serious. |
id |
APM-1_3f65e0ad81c550fd5421d493093f4d94 |
---|---|
oai_identifier_str |
oai:scielo:S1516-31802022000300372 |
network_acronym_str |
APM-1 |
network_name_str |
São Paulo medical journal (Online) |
repository_id_str |
|
spelling |
Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective studyFavipiravir [supplementary concept]COVID-19PneumoniaCoronavirus disease 2019Adverse effectAviganABSTRACT BACKGROUND: Favipiravir is generally used in treating coronavirus disease 2019 (COVID-19) pneumonia in Turkey. OBJECTIVE: To determine the side effects of favipiravir and whether it is a good treatment option. DESIGN AND SETTING: Retrospective study conducted in Atatürk Chest Diseases and Chest Surgery Training and Research Hospital, Ankara, Turkey. METHODS: 357 patients who completed favipiravir treatment at the recommended dose were included. 37 patients with drug side effects and 320 patients without drug side effects were examined in two groups. RESULTS: Side effects were observed in 37 (10.36%) out of 357 patients using favipiravir. The most common side effect was liver dysfunction, in 26 (7.28%) of the patients. The following other side effects were also observed: diarrhea (1.4%), nausea (0.84%), abdominal pain (0.28%) and thrombocytopenia (0.28%). One patient (0.28%) presented both increased transaminases and nausea. CONCLUSION: In this study, it was determined that favipiravir may constitute an alternative for treating COVID-19 pneumonia given that its side effects are generally well tolerated and not serious.Associação Paulista de Medicina - APM2022-06-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802022000300372Sao Paulo Medical Journal v.140 n.3 2022reponame:São Paulo medical journal (Online)instname:Associação Paulista de Medicinainstacron:APM10.1590/1516-3180.2021.0489.r1.13082021info:eu-repo/semantics/openAccessErgür,Figen ÖztürkYıldız,MuratŞener,Melahat UzelKavurgacı,SunaOzturk,Ayperieng2022-05-12T00:00:00Zoai:scielo:S1516-31802022000300372Revistahttp://www.scielo.br/spmjhttps://old.scielo.br/oai/scielo-oai.phprevistas@apm.org.br1806-94601516-3180opendoar:2022-05-12T00:00São Paulo medical journal (Online) - Associação Paulista de Medicinafalse |
dc.title.none.fl_str_mv |
Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective study |
title |
Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective study |
spellingShingle |
Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective study Ergür,Figen Öztürk Favipiravir [supplementary concept] COVID-19 Pneumonia Coronavirus disease 2019 Adverse effect Avigan |
title_short |
Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective study |
title_full |
Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective study |
title_fullStr |
Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective study |
title_full_unstemmed |
Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective study |
title_sort |
Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective study |
author |
Ergür,Figen Öztürk |
author_facet |
Ergür,Figen Öztürk Yıldız,Murat Şener,Melahat Uzel Kavurgacı,Suna Ozturk,Ayperi |
author_role |
author |
author2 |
Yıldız,Murat Şener,Melahat Uzel Kavurgacı,Suna Ozturk,Ayperi |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Ergür,Figen Öztürk Yıldız,Murat Şener,Melahat Uzel Kavurgacı,Suna Ozturk,Ayperi |
dc.subject.por.fl_str_mv |
Favipiravir [supplementary concept] COVID-19 Pneumonia Coronavirus disease 2019 Adverse effect Avigan |
topic |
Favipiravir [supplementary concept] COVID-19 Pneumonia Coronavirus disease 2019 Adverse effect Avigan |
description |
ABSTRACT BACKGROUND: Favipiravir is generally used in treating coronavirus disease 2019 (COVID-19) pneumonia in Turkey. OBJECTIVE: To determine the side effects of favipiravir and whether it is a good treatment option. DESIGN AND SETTING: Retrospective study conducted in Atatürk Chest Diseases and Chest Surgery Training and Research Hospital, Ankara, Turkey. METHODS: 357 patients who completed favipiravir treatment at the recommended dose were included. 37 patients with drug side effects and 320 patients without drug side effects were examined in two groups. RESULTS: Side effects were observed in 37 (10.36%) out of 357 patients using favipiravir. The most common side effect was liver dysfunction, in 26 (7.28%) of the patients. The following other side effects were also observed: diarrhea (1.4%), nausea (0.84%), abdominal pain (0.28%) and thrombocytopenia (0.28%). One patient (0.28%) presented both increased transaminases and nausea. CONCLUSION: In this study, it was determined that favipiravir may constitute an alternative for treating COVID-19 pneumonia given that its side effects are generally well tolerated and not serious. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-06-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802022000300372 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802022000300372 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/1516-3180.2021.0489.r1.13082021 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Associação Paulista de Medicina - APM |
publisher.none.fl_str_mv |
Associação Paulista de Medicina - APM |
dc.source.none.fl_str_mv |
Sao Paulo Medical Journal v.140 n.3 2022 reponame:São Paulo medical journal (Online) instname:Associação Paulista de Medicina instacron:APM |
instname_str |
Associação Paulista de Medicina |
instacron_str |
APM |
institution |
APM |
reponame_str |
São Paulo medical journal (Online) |
collection |
São Paulo medical journal (Online) |
repository.name.fl_str_mv |
São Paulo medical journal (Online) - Associação Paulista de Medicina |
repository.mail.fl_str_mv |
revistas@apm.org.br |
_version_ |
1754209268638154752 |